Attempts to associate methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism with hypertension have been extensively evaluated, but mostly in Caucasians. We therefore meta-analysed this polymorphism in association with hypertension and hypertensionin-pregnancy (HIP) among Chinese subjects. A randomeffects model was applied irrespective of between-study heterogeneity, which was evaluated by subgroup and meta-regression analyses. Study quality was assessed in duplicate. Publication bias was weighed using Egger's test and funnel plot. Data on 20 qualified studies totalling 4461 Chinese subjects were meta-analysed. In overall allelic/genotypic models, carriers of 677T or 677TT were consistently at significantly increased risk of developing hypertension and HIP. No between-study heterogeneity was identified for all genetic models, with the exception for contrast of allele 677T versus 677C in hypertension association studies (P ¼ 0.03), and the dominant contrast in HIP association studies (P ¼ 0.025). Both the subgroup and meta-regression analyses indicated that study design was a potential source of between-study heterogeneity. Funnel plot and Egger's test suggested no evidence of publication bias. Taken together, our results supported the notion that carriers of 677T or 677TT were at significantly increased risk of developing hypertension and HIP, but indicated caution in interpreting this result, because the study design made marginal significant contribution to the heterogeneity.
Introduction
The cause of hypertension is multifactorial; part of it is due to genetic determinants. 1 Although hundreds of potential candidate genes have been investigated with regard to human and rat hypertension, the overall genetic picture remains unclear. 2 However, great caution needs to be taken in interpreting association studies, because false-positive results may frequently occur, mostly attributable to studies with individually low statistical power. 3 In this respect, meta-analyses may provide an opportunity to help identify credible associations. 4 In the present study, we decided to pool data from individual studies that evaluated the effect of an exonic polymorphism C677T or Ala222Val (rs1801133) in methylenetetrahydrofolate reductase (MTHFR) gene on hypertension and hypertensionin-pregnancy (HIP). Previously, many association studies examined the relationship of C677T polymorphism with hypertension and HIP; the results, however, were often irreproducible. [5] [6] [7] In addition, because of the population heterogeneity of genetic background, it is essential to construct a database of polymorphisms related to hypertension in each racial or ethnic group. 8 To fully address this issue and to minimise genetic background noise, we centred on Chinese populations and meta-analysed the association of MTHFR C677T polymorphism with hypertension and HIP, while addressing heterogeneity, as well as publication bias.
Methods
Search strategy for identification of studies Publications were identified by searching PubMed and EMBASE, as well as China Biological Medicine (http://www.imicams.ac.cn) and Wanfang (http:// www.wanfangdata.com.cn) databases for those conducted in Chinese populations and written in English or Chinese language as of 12 November 2010. Reference lists of the retrieved articles and systematic reviews were also checked for citations of studies that were not initially identified. If more than one geographic or ethnic groups were included in one publication, each group was treated separately.
Boolean combinations of keywords used for searching were (hypertension OR hypertension in pregnancy OR pregnancy-induced hypertension OR preeclampsia OR eclampsia OR gestational hypertension) AND (methylenetetrahydrofolate reductase OR MTHFR) AND (gene OR allele OR genotype OR mutation OR variant OR variation OR polymorphism).
Inclusion/exclusion criteria
Qualified studies met the following criteria: (i) evaluation of MTHFR C677T polymorphism with hypertension or HIP among unrelated Chinese subjects; (ii) case-control or cross-sectional study, regardless of sample size, using either a hospitalbased or a population-based design; (iii) sufficient data on C677T genotype counts between patients and controls for estimating the odds ratio (OR) and 95% confidence interval (CI) and (iv) diagnosis of hypertension patients based on the criteria of systolic blood pressure X140 mm Hg or diastolic blood pressure X90 mm Hg. For duplicate publications, the study with the small data set was excluded.
Extracted information
Two authors (WN and YQ) independently extracted and tabulated the following information from each qualified study: first author's name, publication date, population ethnicity, study design, and baseline characteristics of participants such as age, gender and the frequency of genotypes between patients and controls. Results were compared and any discrepancies were adjudicated by a discussion until a consensus was reached. Moreover, for the sake of consistency, continuous variables expressed as mean ± standard error were converted to mean ± s.d.
Statistical analysis
In this meta-analysis, we assessed the association of 677T allele with hypertension or HIP or both relative to 677C allele (allelic model), as well as the association of homozygote comparison (677TT versus 677CC), the dominant model (677TT plus 677CT versus 677CC) and the recessive model (677TT versus 677CC plus 677CT). Unadjusted OR corresponding to 95% CI was used to compare contrasts of alleles or genotypes between patients and controls.
Deviation from Hardy-Weinberg equilibrium was assessed using Pearson w 2 -test. The random-effects model using DerSimonian and Laird method was employed to bring the individual effect-size estimates together, irrespective of between-study heterogeneity. Heterogeneity was evaluated by the I 2 statistic, which was documented for the percentage of the observed between-study variability because of heterogeneity rather than chance, with its values ranging 0-100% (I 2 ¼ 0-25%, no heterogeneity; I 2 ¼ 25-50%, moderate heterogeneity; I 2 ¼ 50-75%, large heterogeneity; I 2 ¼ 75-100%, extreme heterogeneity). 9 In addition, random-effects-based metaregression, assuming a normal distribution for the residual errors with both a within-studies and an additive between-studies component of variance, was applied to estimate the extent to which one or more study-level covariates explain heterogeneity among the individual ORs.
Moreover, cumulative meta-analyses were performed according to the ascending date of publication in order to identify the influence of the firstpublished study on the subsequent publications, and the evolution of the combined estimates over time. 10 Furthermore, to identify potential influential studies, sensitivity analyses were undertaken by removing an individual study each time to check whether any of these estimates can bias the overall estimate. Likewise, subgroup analyses were conducted after stratifying studies were performed on various ethnic/geographic populations or studies with different study designs.
Finally, evidence for publication bias was assessed using Egger's test and visual funnel plot inspection. The Egger's test detects funnel plot asymmetry by determining whether the intercept deviates significantly from zero in a regression of the standardised effect estimates against their precision.
Probability less than 0.05 was judged significant, with the exception of the I 2 statistic and publication tests, where a significance level of less than 0.1 was chosen. Statistical analyses were performed using STATA version 11.0 (StataCorp LP, College Station, TX, USA) for windows.
Results

Search results and study characteristics
In total, 44 potentially relevant studies published in both Chinese and English languages were identified, whereas only 20 studies met our inclusion/exclusion criteria. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The detailed selection process is presented in Figure 1 . Of these 20 qualified studies, 9 were performed in association with hypertension and 11 with HIP, totalling 2300 patients and 2161 controls.
As shown in Table 1 , the overall frequency of MTHFR 677T allele was 44.3% in patients and 34.9% in controls for all qualified studies (n ¼ 20), which was similar in association studies of hypertension (43.5% in patients and 34.9% in controls) and HIP (46.0% in patients and 35.2% in controls). Genotype frequencies of C677T polymorphism were within the Hardy-Weinberg equilibrium in control groups of all studies (P40.05), which signified appropriate population selection. All studies except one in a Mongolian population 16 were conducted in Han Chinese. (Figure 2b ).
Genetic models
Intermediate associations were identified in the dominant and recessive models of inheritance for C677T polymorphism ( Figure 3 ). For example, in the dominant model, contrast of 677T allele carriers (677TT þ 677CT) versus those with 677CC homozygote produced an OR of 1.57 (95% CI: 1.30-1.90; Po0.0005) for all studies, 1.50 (95% CI: 1.20-1.87; Po0.0005) for hypertension association studies and 1.63 (95% CI: 1.18-2.24; P ¼ 0.003) for HIP association studies.
When we restricted analyses to studies on populations of Han descent, the overall and stratified resultant estimates showed no material changes for all genetic models.
Test of heterogeneity
The I 2 statistic indicated no significant between-study heterogeneity for all genetic models of C677T polymorphism, with the exception of contrast of allele 677T versus 677C in hypertension association studies (P ¼ 0.03, Figure 2a ) and the dominant contrast in HIP association studies (P ¼ 0.025, Figure 3a) .
Contrastingly, performing random-effects metaregression on various study-level covariates revealed no significance (P40.05). For hypertension association studies, we observed only marginal association of study design (P ¼ 0.075 for allelic model and P ¼ 0.082 for dominant model) after modelling age, gender (percentage of males), study design (population-based versus hospital-based) and geographic region (north versus south as demarcated by the Qinling Mountains of China's Huaihe River). For HIP association studies, we modelled only age, gestational weeks, study design and geographic region because all subjects were female and all studies were based on a hospitalbased design.
Cumulative and sensitivity analyses
In cumulative meta-analyses, the pooled ORs for both allelic and genotypic models tended to be stable following the year 2003, and the associations reached accruing significance with accumulation of more data over time for both overall and stratified analyses. Generally in sensitivity analyses, no single study was observed to strongly influence the overall results. Moreover, after restricting the analyses to Han Chinese, the risk magnitude from both cumulative and sensitivity analyses remained almost unchanged (data not shown).
Additionally, in hypertension association studies, we performed subgroup analyses by dividing the studies according to the study design, and a consistent trend for all allelic/genotypic models was found, with a stronger association identified in hospital-based studies than population-based studies (Supplementary Figure 1) . Further grouping studies according to geographic region yielded no (Figure 4 ).
Discussion
Various attempts to summarise the existing evidence regarding association of MTHFR C677T polymorphism with hypertension and HIP have been made in the past decade, but always in Caucasian populations. 31 This meta-analysis, including 4461 Chinese subjects from 20 studies, investigated this association. Although some statistical biases could not be eliminated and there was a possibility of between-study heterogeneity, our results consistently suggested that carriers of 677T or 677TT were at significantly increased risk of developing hypertension and gestational hypertension.
To the authors' knowledge, this study is to date the most comprehensive meta-analysis for MTHFR C677T in association with hypertension in Chinese.
Recently, another meta-analysis including 26 worldwide studies was conducted by Qian et al. 32 to investigate MTHFR C677T with hypertension risk. Intuitively, the present study is seemingly superfluous and is just a part of the aforementioned study. 32 Our results, however, enjoyed apparent superiority over that in Qian et al.'s study in terms of the following aspects: first, compared with the Qian et al.'s study, 32 our meta-analysis included a total of 20 Chinese populations with 4461 subjects, which was almost twice higher than the number mentioned in the aforementioned study; 32 second, apart from subgroup analyses, we additionally applied meta-regression analyses to investigate potential sources of between-study heterogeneity, with both methods coming to an agreement that study design made marginal significant contribution to the heterogeneity, which was not reported in Qian et al.'s study; 32 third, our study took account of possible genetic background noise arising from different racial/ethnic populations by studying Chinese only, yielding a higher signal-to-noise ratio for detecting the role of MTHFR C677T polymorphism in hypertension risk. Therefore, our study can provide additional precision to characterise the genetic susceptibility of MTHFR C677T polymorphism to hypertension.
The most noteworthy finding of this study-the significant and consistent association of MTHFR C677T polymorphism with hypertension and HIPimplied that the mechanism whereby the MTHFR C677T variant, if involved, exerted its effect on hypertension and gestational hypertension might be identical. The biological rationale for implicating MTHFR C677T polymorphism in hypertension is based on the fact that MTHFR catalyses the formation of 5-methylenetetrahydrofolate, a co-substrate for the conversion of homocysteine to methionine, 33 with the 677TT genotype, via the creation of a thermolabile enzyme isoform, associating with elevated homocysteine, which may predispose to atherosclerosis by injuring the vascular endothelium, further resulting in hypertension, 34 which is consistent with the association results in this study. Therefore, it is reasonable to expect that multiple genetic and/or physiological safeguards have developed to maintain homocysteine within a range of physiologically acceptable levels, in a variety of environmental conditions. In this respect, we failed to obtain all of the study-level covariates to account for this significant heterogeneity, because a number of studies did not report relevant information, precluding a more robust assessment of sources of heterogeneity. Another important finding was that in this metaanalysis, study design was identified as a potential source of between-study heterogeneity by both metaregression and subgroup analyses for MTHFR C677T polymorphism, with stronger association observed in hospital-based studies than in populationbased studies. This phenomenon might be attributable to the fact that in hospital-based studies, poor comparability between cases and controls might confound the true association in light of a regional specialty for the disease under study and the differential hospitalisation rates between cases and controls. 35 As most of our studies recruited subjects from only one hospital, the hospital controls may have a narrower socioeconomic profile. In contrast, controls drawn from the general population might be representative of the true population of those without the disease. 36 Even so, population selection bias is unlikely to affect the validity of our findings, because genotype frequencies of C677T polymorphism respected Hardy-Weinberg equilibrium in all control groups. It is thus speculated that in this meta-analysis, the magnitude of association between MTHFR C677T and hypertension might be overestimated in the overall OR estimates. Although this might not affect the final conclusions, more studies are warranted to quantify the effect size reliably.
Despite the clear strength of our study, including large sample sizes and robust statistical analyses, some limitations merit serious consideration. First, all included studies had the case-control design; the results need to be confirmed in future prospective cohort studies. Second, for hypertension association studies, most studies have recruited subjects aged X50 years, for whom environmental factors are likely to contribute more prominently than the genetic component to the development of hypertension, suggesting that large association studies in a younger Chinese population of hypertensive subjects are of added interest. 37 Third, although we underscore the role of C677T polymorphism as markers of a high susceptibility to hypertension and gestational hypertension, our results may be generalisable only to the Chinese population. Last but not least, in this study, we only focused on MTHFR C677T, and did not evaluate other susceptible genes or polymorphisms. It is possible that the potential role of C677T polymorphism is diluted or masked by the gene-gene or gene-environment interactions. Thus, the jury must refrain from drawing a conclusion until a large, well-performed cohort study confirms or refuses our results.
In summary, this meta-analysis strengthened and extended previous findings on MTHFR C677T polymorphism in Chinese, by showing that carriers of 677T or 677TT were at significantly increased risk of developing hypertension and gestational hypertension. However, our study indicated caution in interpreting these results because study design might be a potential source of between-study heterogeneity. Further studies are required to investigate MTHFR gene adjacent markers to confirm whether the present association is causal or due to linkage disequilibrium.
